Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Drug-induced dystonia

Full Text:


Drug-induced dystonia (DID) is a rarely diagnosed adverse reaction to a sufficiently large number of drugs. Acute DID (ADID) occurs soon after starting to take a drug or raising its dose, and switching from one antipsychotic medication to another, especially to its injectable dosage form. Tardive DID (TDID) develops a few months or years after starting drug intake or 3 months after stopping therapy. The diagnosis of TDID is based on the persistence of dystonic hyperkinesis for more than 1 month, the use of a dopamine receptor blocking agent, and the absence of other causes of its development. The risk factors for DID are male sex; young age (less than 30 years of age); a history of dystonic reactions; hypocalcemia, alcohol use while taking the drug. DID is most commonly related to therapy with antipsychotics, metoclopramide, antidepressants, and antiepileptic drugs. The short-term use of anticholinergic drugs (benzotropin, diphenhydramine) is effective in treating ADID. Anticholinergic drugs and atypical antipsychotics (clozapine, quetiapine), benzodiazepines, muscle relaxants (baclofen), and dopamine reuptake inhibitors (tetrabenazine) are used to treat TDID. To prevent DID, it is very important that a physician should be aware of that this unwanted adverse reaction may occur and that a drug with the lowest risk for DID should be chosen.

About the Authors

T. M. Ostroumova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Olga D. Ostroumova

11, Rossolimo St., Build. 1, Moscow 119021


V. A. Tolmacheva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

11, Rossolimo St., Build. 1, Moscow 119021

O. D. Ostroumova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation

11, Rossolimo St., Build. 1, Moscow 119021,

2/1, Barrikadnaya St., Build. 1, Moscow 125993

V. A. Parfenov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

11, Rossolimo St., Build. 1, Moscow 119021


1. Tisdale JE, Miller DA, eds. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018.

2. Medication-induced movement disorders and other adverse effects of medication. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.

3. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335-46. doi: 10.1212/wnl.32.12.1335

4. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management. CNS Drugs. 2002;16(3):165-74. doi: 10.2165/00023210-200216030-00003

5. Stübner S, Padberg F, Grohmann R, et al. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry. 2000 Aug;61(8):569-74. doi: 10.4088/JCP.v61n0805

6. Levin OS. Drug dyskinesia. Sovremennaya terapiya v psikhiatrii i nevrologii. 2014;(3):4-13 (In Russ.).

7. Friedman JH, ed. Medication-induced movement disorders. Cambridge: Cambridge University Press; 2015. Chapter 2, Acute dystonia; P. 20-30. doi: 10.1017/CBO9781107588738.003

8. Digby G, Jalini S, Taylor S. Medicationinduced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit. BMJ Case Rep. 2015 Sep 21;2015:bcr2014207215. doi: 10.1136/bcr-2014-207215

9. Vaiman EE, Shnayder NA, Neznanov NG, Nasyrova RF. Antipsychotic-induced tardive dyskinesia as a serious adverse effect in the psychopharmacotherapy of schizophrenia. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):4-13. doi: 10.14412/2074-2711-2019-4-4-13 (In Russ.).

10. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999 Mar 10;52(4):782-5. doi: 10.1212/wnl.52.4.782

11. Bernagie C, Danckaerts M, Wampers M, et al. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis. CNS Drugs. 2016;30(9):807-18. doi: 10.1007/s40263-016-0367-y

12. Martino D, Karnik V, Osland S, et al. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and metaanalysis. Can J Psychiatry. 2018;63(11):730-9. doi: 10.1177/0706743718777392

13. Valkova M, Stamenov B, Peychinska D, et al. Metoclopramide-induced extrapyramidal signs and symptoms – brief review of literature and case report. J IMAB. 2014;20(6):539-41. doi: 10.5272/jimab.2014206.539

14. Jo YY, Kim YB, Yang MR, et al. Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit – A case report. Korean J Anesthesiol. 2012 Sep;63(3):274-6. doi: 10.4097/kjae.2012.63.3.274. Epub 2012 Sep 14.

15. Mörkl S, Seltenreich D, Letmaier M, et al. Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance programme. World J Biol Psychiatry. 2020 Apr;21(4):308-16. doi: 10.1080/15622975.2019.1648871. Epub 2019 Aug 7.

16. Wernicke JF. Safety and side effect profile of fluoxetine. Expert Opin Drug Saf. 2004 Sep;3(5):495-504. doi: 10.1517/14740338.3.5.495

17. Beyazyüz M, Albayrak Y. Imipramine induced acute dystonia in a child with enuresis nocturna: a case report. Eur Psychiatry. 2013;28(Suppl 1):1. doi: 10.1016/S0924-9338(13)76911-6

18. Ornadel D, Barnes EA, Dick DJ. Acute dystonia due to amitriptyline. J Neurol Neurosurg Psychiatry. 1992 May;55(5):414. doi: 10.1136/jnnp.55.5.414

19. Hiremath SB, Desai M. Amitriptyline induced cervical dystonia. J Scient Soc. 2016;43(1):38-40. doi: 10.4103/0974-5009.175458

20. Sonmez I, Kosger F. Venlafaxine-induced acute dystonia: a case report. J Psychiatry Neurol Sci. 2015;28:374-7. doi: 10.5350/DAJPN2015280410

21. Fonseca L, Rodrigues M, Machado A. Psychogenic movement disorder after a venlafaxine-induced dystonia. Mov Disord. 2010 Mar 15;25(4):506-7. doi: 10.1002/mds.22910

22. Zadikoff C, Munhoz RP, Asante AN, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):147-51. doi: 10.1136/jnnp.2006.100222. Epub 2006 Sep 29.

23. Pina MA, Modrego PJ. Dystonia induced by gabapentin. Ann Pharmacother. 2005 Feb;39(2):380-2. doi: 10.1345/aph.1E503. Epub 2005 Jan 11.

24. Fadare JO, Owolabi LF. Carbamazepineinduced dystonia, a case report. Neurology Asia. 2009;14(2):165-6.

25. Bansal S, Gill M, Bhasin C. Carbamazepine-induced dystonia in an adolescent. Indian J Pharmacol. May-Jun 2016;48(3):329-30. doi: 10.4103/0253-7613.182879

26. Palomeras E, Sanz P, Cano A, et al. Dystonia in a patient treated with propranolol and gabapentin. Arch Neurol. 2000;57(4):570-1. doi: 10.1001/archneur.57.4.570

27. Marrero-Gonzalez PC, Ruano OL, Catalano G, et al. Dystonia associated with lamotrigine therapy: a case report and review of the literature. Curr Drug Saf. 2014;9(1):60-2. doi: 10.2174/18715249113136660060

28. Strjer R, Strous RD, Bar F, et al. Segmental dystonia as the sole manifestation of carbamazepine toxicity. Gen Hosp Psychiatry. 2002;24(2):114-5. doi: 10.1016/s0163-8343(01)00177-3

29. Chen WH, Huang WL, Hsieh MH. Metformin-induced acute dystonia in a schizophrenic patient treated with sulpiride and clozapine. Psychiatry Clin Neurosci. 2016;70(8):362-3. doi: 10.1111/pcn.12405

30. Song X, Hu Z, Zhang H. Acute dystonia induced by lamivudine. Clin Neuropharmacol. Jul-Aug 2005;28(4):193-4. doi: 10.1097/01.wnf.0000172367.71932.61

31. Dhikav V, Anand KS. Acute dystonic reaction with rivastigmine. Int Psychogeriatr. 2013;25(8):1385-6. doi: 10.1017/S104161021300029X

32. Yilmaz-Topa Ö, Tuygun N, Akca H, et al. Cetirizine and albendazole induced dystonia in a child. Turk J Pediatr. Jul-Aug 2015;57(4):407-8.

33. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463- 9. doi: 10.1212/WNL.0b013e31829d86b6

For citation:

Ostroumova T.M., Tolmacheva V.A., Ostroumova O.D., Parfenov V.A. Drug-induced dystonia. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):4-8.

Views: 439

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)